Format

Send to

Choose Destination
Prev Med. 2017 Oct;103:60-65. doi: 10.1016/j.ypmed.2017.07.027. Epub 2017 Jul 29.

Surveillance of high-grade cervical cancer precursors (CIN III/AIS) in four population-based cancer registries, United States, 2009-2012.

Author information

1
Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: Eze5@cdc.gov.
2
Northrup Grumman, Atlanta, GA, United States.
3
Division of Sexually Transmitted Disease Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States.
4
Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.
5
Los Angeles County Cancer Surveillance Program, Los Angeles, CA, United States.
6
Louisiana Tumor Registry, Epidemiology Program, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA, United States.
7
Michigan Cancer Surveillance Program, Lansing, MI, United States.
8
Kentucky Cancer Registry, Lexington, KY, United States.
9
Advanced Technical Logistics, Inc., Newnan, GA, United States.
10
Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA, United States.

Abstract

Surveillance of cervical intraepithelial neoplasia grade III (CIN III) and adenocarcinoma in situ (AIS) is important for determining the burden of a preventable disease, identifying effects of vaccination on future diagnoses, and developing targeted programs. We analyzed population-based rates of high-grade cervical cancer precursor lesions using data from four central cancer registries (diagnosis years 2009-2012 from Louisiana, Kentucky, Michigan, and diagnosis years 2011-2012 from Los Angeles) by age, race, and histology. We also compared rates of precursors to invasive cancers. With 4 complete years of data from Michigan, we were able to conduct a trend analysis for that state. Data analysis was conducted in Atlanta during 2016. Kentucky reported the highest rate of CIN III/AIS (69.8), followed by Michigan (55.4), Louisiana (42.3), and Los Angeles (19.2). CIN III/AIS rates declined among women in Michigan by 37% each year for women aged 15-19, 14% for those aged 20-24, and 7% for those aged 25-29. Rates of CIN III/AIS vary by registry, and were higher than invasive cancer. In Michigan, declines in CIN III/AIS among women aged 15-29 are likely related in part to updated screening recommendations, and to the impact of human papillomavirus vaccination.

KEYWORDS:

Cervical cancer; Cervical intraepithelial neoplasia; HPV; HPV vaccines; Population-based cancer registries

PMID:
28765084
PMCID:
PMC5591775
[Available on 2018-10-01]
DOI:
10.1016/j.ypmed.2017.07.027
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center